TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18383334
Drug: Methacholine challenge
Normalized name: Methacholine Challenge Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine challenge (PC20 < or = 8.0 mg/ml) in nonatopic girls
Study: 18383334
Drug: Methacholine challenge
Normalized name: Methacholine Challenge Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine challenge (PC20 < or = 2.0 mg/ml) in atopic boys
Study: 12370838
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (glipizide GITS + metformin)
Study: 2147787
Drug: Saliva stimulants
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saliva stimulants (Salivin lozenge)
Study: 29715369
Drug: PEG/PG QID
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG/PG QID (four times daily)
Study: 15670536
Drug: Ranolazine 400
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine 400 mg three times daily
Study: 31277446
Drug: Mediterranean diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean diet with 2-3 weekly servings of fresh, lean pork (MedPork)
Study: 22415333
Drug: Famotidine treatment
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Famotidine treatment
Study: 11835120
Drug: Technosphere/Insulin (TI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technosphere/Insulin (TI) via inhalation
Study: 10049414
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg twice daily) and Rowachol (2 tablets 3 times daily)
Study: 7586262
Drug: Steroid-eluting lead
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-eluting lead (Medtronic model 4068)
Study: 2338106
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without any antiemetic treatment
Study: 111546
Drug: Lactinex (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactinex (Lactobacillus acidophilus and L bulgaricus), 1 packet four times daily for the first five days of ampicillin therapy
Study: 24131736
Drug: PF-04360365 (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04360365 (0.1, 0.5, 1, 5, or 10 mg/kg)
Study: 17890232
Drug: Prandial insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prandial insulin aspart three times daily
Study: 17890232
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin detemir once daily (twice if required)
Study: 18020110
Drug: Cholinesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitors (donepezil, rivastigmine, galantamine)
Study: 18020110
Drug: N-methyl-D-aspartate receptor
Normalized name: N-methyl-D-aspartate receptor antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-methyl-D-aspartate receptor antagonist (memantine)
Study: 9892909
Drug: Calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol ointment (50 microg/g)
Study: 9892909
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate (64 mg/g) and salicylic acid (0.03 g/g) ointment
Study: 8070028
Drug: Etoposide phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide phosphate (EP) given at maximum tolerated doses of 100 mg/m2 (daily for 5 days) and 150 mg/m2 (on days 1, 3, and 5)
Study: 30020092
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of daily living practiced using real materials
Study: 18559367
Drug: Amoxicillin (HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (HIV infected)
Study: 18559367
Drug: Amoxicillin (HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (HIV uninfected)
Study: 10844161
Drug: Pycnogenol (French
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol (French maritime pine bark extract), 100 mg x 3/day
Study: 9070128
Drug: Cytotoxic drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic drug delivery system using 5-fluorouracil applied directly to the cervix.
Study: 2878839
Drug: Triacetin-prostaglandin E2-gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triacetin-prostaglandin E2-gel
Study: 29140138
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg b.i.d.)
Study: 17638034
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment plus routine care
Study: 16842664
Drug: Magnetocardiography (MCG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetocardiography (MCG) in CAD group
Study: 11027812
Drug: Formalin-inactivated JE
Normalized name: formalin
DrugBank: Formaldehyde (DB03843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formalin-inactivated JE and placebo vaccines
Study: 25976090
Drug: Healing Touch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healing Touch (noninvasive energy therapy) for 15 minutes prior to biopsy procedure
Study: 25124490
Drug: Oligonol 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligonol 200 mg
Study: 19079142
Drug: 360 degree
Normalized name: NEEDLE 20G 1IN BENT 90 DEGREES
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 degree anterior capsule polishing (group 1)
Study: 19079142
Drug: No anterior
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anterior capsule polishing (group 2, controls)
Study: 15893381
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate (MgSO(4)) administered at 150-200 mg/h for 24 hours (n=22)
Study: 15893381
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% administered intravenously (n=19)
Study: 6349719
Drug: Androgen alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen alone (concurrent STANDARD care controls)
Study: 22236345
Drug: 5.0 mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg/ml bupivacaine infusion at 2 ml/h for 48 hours
Study: 10716466
Drug: Gemfibrozil (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (1,200 mg/day)
Study: 12384411
Drug: Idarubicin (IDA)
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idarubicin (IDA) alone, 10 mg/m² daily for 6 days
Study: 7753585
Drug: Albendazole treatment
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole treatment in undernourished children (Z-score < -1)
Study: 19104723
Drug: Spironolactone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25 mg/day) with ACE inhibitor
Study: 19716598
Drug: Tiotropium (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (18 microg once daily)
Study: 18209516
Drug: Mirtazapine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (30 mg)
Study: 10325901
Drug: Pulsed dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed dose oxygen delivery (PDOD) system
Study: 10325901
Drug: Continuous flow
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous flow oxygen at 2 l/min
Study: 6352272
Drug: penbutolol 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: penbutolol 40 mg
Study: 29798059
Drug: Flunarizine 10
Normalized name: flunarizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine 10 mg daily for 3 months along with betahistine 12 mg Tid for 48 h during episodes
Study: 24830937
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (30 mL)
Study: 12229133
Drug: 1 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg.kg‐1 flurbiprofen i.v. at the end of surgery
Study: 12229133
Drug: 1 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg.kg‐1 flurbiprofen i.v. before the start of surgery
Study: 9454160
Drug: Conventional irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional irradiation (once a day, 2.2 Gy to a total dose of 70 Gy to 77 Gy)
Study: 2108575
Drug: tissue plasminogen
Normalized name: Tissue plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tissue plasminogen activator (t-PA) 100 to 150 mg intravenously over 6 to 8 hours
Study: 375849
Drug: Diflunisal (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal (750 mg per day)
Study: 29493562
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (systolic blood pressure target of less than 120 mmHg)
Study: 25112584
Drug: naloxegol 25
Normalized name: naloxegol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naloxegol 25 mg/day
Study: 25112584
Drug: usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: usual care (UC; investigator-chosen laxative regimen)
Study: 16182025
Drug: Follow-up without
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up without therapy (Control)
Study: 16182025
Drug: Bone setting
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone setting (5 weekly sessions)
Study: 29772111
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 50 mg
Study: 8775936
Drug: Angiotensin-converting-enzyme inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting-enzyme inhibitors
Study: 2776469
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg flurbiprofen twice daily
Study: 3508329
Drug: 375 mg
Normalized name: niacin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg naproxen twice daily
Study: 7128668
Drug: Amezinium 30
Normalized name: amezinium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amezinium 30 mg
Study: 28949089
Drug: Placebo (wrapped
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (wrapped isovolumetric saline infusion)
Study: 28949089
Drug: IVIG (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (4 doses of 0.5 g/kg) and RTX (375 mg/m2)
Study: 27788771
Drug: Preparation with
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation with continuous irrigation
Study: 24411144
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (weekly one hour sessions for eight weeks)
Study: 20609468
Drug: Olaparib 400
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 400 mg twice daily
Study: 29258133
Drug: Daily constancy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily constancy test
Study: 10445416
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg per day for 10 days)
Study: 10445416
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (diet, corsil)
Study: 7598769
Drug: Plasma-derived HB
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma-derived HB vaccine with yellow fever vaccine
Study: 7598769
Drug: Recombinant HB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant HB vaccine with yellow fever vaccine
Study: 7598769
Drug: Polio vaccine
Normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polio vaccine with plasma-derived HB vaccine
Study: 7598769
Drug: Polio vaccine
Normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polio vaccine with recombinant HB vaccine
Study: 2262356
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C - 60Co 60 Gy in 30 fractions plus chemotherapy (5 Fu, 250 mg/m2/IV every 2 days)
Study: 902232
Drug: Methanol extraction
Normalized name: methanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methanol extraction residue (MER) of Bacille‐Calmette‐Guerin (BCG) in addition to radiotherapy and/or chemotherapy
Study: 902232
Drug: Radiotherapy and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy and/or chemotherapy alone
Study: 25826870
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (5% solution, 20 ml/day for 20 days)
Study: 25826870
Drug: Cytoflavin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin (10 ml intravenously, twice a day for 10 days)
Study: 25826870
Drug: Cytoflavin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin (20 ml/day for first 10 days, 10 ml/day for next 10 days)
Study: 16405547
Drug: >=2 contrast
Approvals — FDA: no, EMA: no, PMDA: no
Description: >=2 contrast injections into the pancreatic duct
Study: 7604809
Drug: Fluvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (40 mg daily)
Study: 8993943
Drug: Ciprofibrate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofibrate (100 mg daily)
Study: 10734016
Drug: 4 microgram/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 microgram/kg IL-10 subcutaneously daily for 90 days
Study: 10734016
Drug: 8 microgram/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 microgram/kg IL-10 subcutaneously daily for 90 days
Study: 8736999
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of opioid receptor density in C57BL/6 mice and DBA/2 mice
Study: 8736999
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of opioid receptor density in AA rats and ANA rats
Study: 1551151
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous (PCA-i.v.) fentanyl
Study: 3926511
Drug: Glucose infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusions
Study: 12462350
Drug: Saline infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusions
Study: 25740265
Drug: QMF149 150/320
Approvals — FDA: no, EMA: no, PMDA: no
Description: QMF149 150/320 μg
Study: 10345150
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (EGb 761) 80 mg twice daily
Study: 10345150
Drug: Betahistine dihydrochloride
Normalized name: Betahistine Dihydrochloride
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine dihydrochloride (BI) 16 mg twice daily
Study: 25311914
Drug: GnRH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH treatment (100 µg)
Study: 28799258
Drug: Helicobacter pylori
Normalized name: HELICOBACTER PYLORI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helicobacter pylori eradication treatment
Study: 16925613
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori treatment
Study: 11253839
Drug: High-dose zidovudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose zidovudine (AZT) 1500 mg/day
Study: 28407338
Drug: Tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine ER 4 mg once daily for 12 weeks
Study: 23377513
Drug: Combination gel
Normalized name: SUNSCREEN-30 PABA-FREE COMBINATION GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination gel (clindamycin phosphate 1.2% and tretinoin 0.025%)
Study: 20650919
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0.75 mg kg(‐1) bolus then infusion 1 mg kg(‐1) h(‐1))
Study: 20650919
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (1.5 mg kg(‐1) bolus and infusion 2 mg kg(‐1) h(‐1))
Study: 20650919
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (3 mg kg(‐1) bolus and infusion 4 mg kg(‐1) h(‐1))
Study: 18772216
Drug: i.v. midazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. midazolam 0.02 mg kg(‐1)
Study: 12088299
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of surgery and radiation therapy
Study: 12088299
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant therapy based on pathologic risk factors
Study: 1676306
Drug: Indomethacin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (75 mg b.d.)
Study: 6357207
Drug: Suprofen 100
Normalized name: Suprofen
DrugBank: Suprofen (DB00870)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suprofen 100 mg + APAP 650 mg
Study: 31269506
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA, 3.0 g/day)
Study: 31269506
Drug: Docosahexaenoic acid
Normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docosahexaenoic acid (DHA, 1.4 g/day)
Study: 22073579
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of long acting beta2 agonist (LABA) and inhaled corticosteroids (ICS)
Study: 11908552
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (Neoral-Sandimmun, 3 mg/kg/day)
Study: 10839074
Drug: Paracetamol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (30 to 50 mg/kg loading dose, followed by 70 to 100 mg/kg/24 hours) plus intramuscular fentanyl citrate (1 microgram/kg)
Study: 8567509
Drug: 8% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% glucose solution with [U‐13C]glucose tracer
Study: 2138049
Drug: Cilazapril (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (1.25 to 5.0 mg/day, single dose)
Study: 3178924
Drug: Midazolam 7.5
Normalized name: midazolam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 7.5 mg
Study: 1535490
Drug: Oxazepam 25
Normalized name: Oxazepam 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam 25 mg
Study: 25238912
Drug: Nut group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nut group (30 g/d of mixed nuts for 6 weeks)
Study: 11774098
Drug: Immunosuppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive therapy with prednisone and cyclophosphamide (n = 18)
Study: 1837974
Drug: Anti‐inflammatory and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti‐inflammatory and anti‐fibrinolytic agents
Study: 16356431
Drug: Extra fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra fluids (intravenous fluid supplementation for 8 hours and oral supplementation for the duration of phototherapy)
Study: 9449498
Drug: Subcutaneous epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous epinephrine (0.01 ml/kg, maximum 0.3 ml [0.3 mg])
Study: 9449498
Drug: Intramuscular epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular epinephrine (0.3 mg from an autoinjector)
Study: 10150837
Drug: Antimetabolites as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimetabolites as pharmacologic modulators of wound healing in conjunction with argon laser suture lysis and small‐incision phacoemulsification techniques
Study: 619949
Drug: Aluminium hydroxide
Normalized name: Aluminium hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminium hydroxide and glycopyrrhonium (combination)
Study: 619949
Drug: Ethanol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.5 g/kg in 10% solution or 0.8 g/kg in 20% solution)
Study: 21704306
Drug: Transdiagnostic cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic cognitive behaviour therapy for eating disorders (CBT‐E)
Study: 14551476
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine (n = 202)
Study: 8792892
Drug: Morphine with
Normalized name: opium alkaloids with morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine with droperidol (10mg droperidol/60 mg morphine)
Study: 1599353
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of sustained-release pseudoephedrine taken twice daily
Study: 7973107
Drug: Nebulised salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised salbutamol (5 mg)
Study: 6229262
Drug: Nebulised ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised ipratropium (0.5 mg)
Study: 6229262
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nebulised salbutamol and ipratropium
Study: 29905663
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) for MST-related PTSD
Study: 24096258
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (375 ml, 41 g of alcohol)
Study: 22584638
Drug: Rocuronium (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (0.9 mg/kg)
Study: 27757709
Drug: Endothelin receptor
Normalized name: Endothelin receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin receptor antagonists
Study: 7924782
Drug: Alanine infusion
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alanine infusion
Study: 3172783
Drug: 0.56 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.56 g/kg ethanol
Study: 27805026
Drug: AERAS-402 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AERAS-402 vaccine